Serge Leyvraz - ARCHIVE

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


249 publications

In press | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | ...
 
Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.
Khoja L., Atenafu E.G., Suciu S., Leyvraz S., Sato T., Marshall E., Keilholz U., Zimmer L., Patel S.P., Piperno-Neumann S. et al. Annals of oncology. Peer-reviewed.
 
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.
Pertesi M., Vallée M., Wei X., Revuelta M.V., Galia P., Demangel D., Oliver J., Foll M., Chen S., Perrial E. et al., 2019/09. Leukemia, 33 (9) pp. 2324-2330. Peer-reviewed.
 
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Montemurro M., Cioffi A., Dômont J., Rutkowski P., Roth A.D., von Moos R., Inauen R., Toulmonde M., Burkhard R.O., Knuesli C. et al., 2018/04/01. Cancer, 124 (7) pp. 1449-1454. Peer-reviewed.
 
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
Casali P.G., Zalcberg J., Le Cesne A., Reichardt P., Blay J.Y., Lindner L.H., Judson I.R., Schöffski P., Leyvraz S., Italiano A. et al., 2017/05/20. Journal of clinical oncology, 35 (15) pp. 1713-1720. Peer-reviewed.
 
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.
Rusakiewicz S., Perier A., Semeraro M., Pitt J.M., Pogge von Strandmann E., Reiners K.S., Aspeslagh S., Pipéroglou C., Vély F., Ivagnes A. et al., 2017. Oncoimmunology, 6 (1) pp. e1137418. Peer-reviewed.
Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.
Royer-Bertrand B., Torsello M., Rimoldi D., El Zaoui I., Cisarova K., Pescini-Gobert R., Raynaud F., Zografos L., Schalenbourg A., Speiser D. et al., 2016/11/03. American journal of human genetics, 99 (5) pp. 1190-1198. Peer-reviewed.
 
Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group.
Kivelä T.T., Piperno-Neumann S., Desjardins L., Schmittel A., Bechrakis N., Midena E., Leyvraz S., Zografos L., Grange J.D., Ract-Madoux G. et al., 2016/08. American journal of ophthalmology, 168 pp. 217-226. Peer-reviewed.
UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation.
Rivolta C., Royer-Bertrand B., Rimoldi D., Schalenbourg A., Zografos L., Leyvraz S., Moulin A., 2016/04. Journal of human genetics, 61 (4) pp. 361-362. Peer-reviewed.
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
Bogaerts J., Sydes M.R., Keat N., McConnell A., Benson A., Ho A., Roth A., Fortpied C., Eng C., Peckitt C. et al., 2015. European Journal of Cancer, 51 (3) pp. 271-281. Peer-reviewed.
Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L., Losi L., Leyvraz S., Benhattar J., 2015. Plos One, 10 (7) pp. e0132977. Peer-reviewed.
 
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Delforge M., Minuk L., Eisenmann J.C., Arnulf B., Canepa L., Fragasso A., Leyvraz S., Langer C., Ezaydi Y., Vogl D.T. et al., 2015. Haematologica, 100 (6) pp. 826-833. Peer-reviewed.
 
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.
Joensuu H., Eriksson M., Collan J., Balk M.H., Leyvraz S., Montemurro M., 2015. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology, 116 (2) pp. 233-238. Peer-reviewed.
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
Leyvraz S., Piperno-Neumann S., Suciu S., Baurain J.F., Zdzienicki M., Testori A., Marshall E., Scheulen M., Jouary T., Negrier S. et al., 2014. Annals of Oncology, 25 (3) pp. 742-746. Peer-reviewed.
High Expression of hTERT and Stemness Genes in BORIS/CTCFL Positive Cells Isolated from Embryonic Cancer Cells.
Alberti L., Renaud S., Losi L., Leyvraz S., Benhattar J., 2014. PLoS One, 9 (10) pp. e109921.
Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy
Orcurto A., Gay B.E., Sozzi W.J., Gilliet M., Leyvraz S., 2014. Case Reports In Dermatology, 6 (1) pp. 80-84. Peer-reviewed.
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Romano E., Michielin O., Voelter V., Laurent J., Bichat H., Stravodimou A., Romero P., Speiser D.E., Triebel F., Leyvraz S. et al., 2014. Journal of Translational Medicine, 12 p. 97.
 
Psychodynamic interventions in cancer care I: psychometric results of a randomized controlled trial.
Ludwig G., Krenz S., Zdrojewski C., Bot M., Rousselle I., Stagno D., Luethi F., Leyvraz S., Stiefel F., 2014. Psycho-Oncology, 23 (1) pp. 65-74. Peer-reviewed.
 
Clinical pharmacokinetics of imatinib and its therapeutic relevance
Widmer N., Gotta V., Haouala A., Blanc J., von Mehren M., Duchosal M., Leyvraz S., Csajka C., Decosterd L.A., Buclin T., 2013. pp. 15-43 dans Akhtari M., Elhemaidi I. (eds.) Imatinib: Chemical structure, pharmacology and adverse effects chap. 2, Nova Science Publishers.
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
Prognostic factors in adult soft tissue sarcoma treated with surgery combined with radiotherapy: a retrospective single-center study on 164 patients.
Cai L., Mirimanoff R.O., Mouhsine E., Guillou L., Leyvraz P.F., Leyvraz S., Gay B., Matzinger O., Ozsahin M., Zouhair A., 2013. Rare Tumors, 5 (4) pp. e55. Peer-reviewed.
 
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
ESMO / European Sarcoma Network Working Group, 2012/10. Annals of Oncology, 23 Suppl 7 (Suppl 7) pp. vii100-vii109.
 
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
ESMO / European Sarcoma Network Working Group, 2012/10. Annals of Oncology, 23 Suppl 7 (Suppl 7) pp. vii92-vii99.
 
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Chirgwin J., Sun Z., Smith I., Price K.N., Thürlimann B., Ejlertsen B., Bonnefoi H., Regan M.M., Goldhirsch A., Coates A.S. et al., 2012/09. Breast Cancer Research and Treatment, 131 (1) pp. 295-306.
18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Orcurto V., Denys A., Voelter V., Schalenbourg A., Schnyder P., Zografos L., Leyvraz S., Delaloye A.B., Prior J.O., 2012. Melanoma Research, 22 (1) pp. 63-69. Peer-reviewed.
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Demetri G.D., Garrett C.R., Schöffski P., Shah M.H., Verweij J., Leyvraz S., Hurwitz H.I., Pousa A.L., Le Cesne A., Goldstein D. et al., 2012. Clinical Cancer Research, 18 (11) pp. 3170-3179.
 
Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
ESMO / European Sarcoma Network Working Group, 2012. Annals of Oncology, 23 Suppl 7 (Suppl 7) pp. vii49-vii55.
 
Home care: a safe and attractive alternative to inpatient administration of intensive chemotherapies.
Lüthi F., Fucina N., Divorne N., Santos-Eggimann B., Currat-Zweifel C., Rollier P., Wasserfallen J.B., Ketterer N., Leyvraz S., 2012. Supportive Care in Cancer, 20 (3) pp. 575-581. Peer-reviewed.
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
 
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M., Lauwers-Cances V., Marit G., Caillot D., Moreau P., Facon T., Stoppa A.M., Hulin C., Benboubker L., Garderet L. et al., 2012. New England Journal of Medicine, 366 (19) pp. 1782-1791.
 
Ocular melanoma: what's new?
Leyvraz S., Keilholz U., 2012. Current Opinion In Oncology, 24 (2) pp. 162-169.
 
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era.
Cassier P.A., Fumagalli E., Rutkowski P., Schöffski P., Van Glabbeke M., Debiec-Rychter M., Emile J.F., Duffaud F., Martin-Broto J., Landi B. et al., 2012. Clinical Cancer Research, 18 (16) pp. 4458-4464.
 
Pas disponible, débrouillez-vous: un scandale inacceptable [Not available, cope with it: an unacceptable scandal].
Aapro M., Dietrich P.Y., Leyvraz S., 2012. Revue Médicale Suisse, 8 (342) pp. 1083-1084.
 
Pharmacokinetic (PK)-based dosage individualization of imatinib: evaluation of efficiency and clinical usefulness
Gotta V., Widmer N., Decosterd L.A., Montemurro M., Leyvraz S., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L. et al., 2012. dans 3rd Symposium of the Swiss Clinical Trial Organisation (SCTO), Personalised Medicine in Clinical Research.
 
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2012. Clinical Pharmacokinetics, 51 (3) pp. 187-201. Peer-reviewed.
Traitement et prophylaxie de la Maladie ThromboEmbolique Veineuse (MTEV)
Centre hospitalier universitaire vaudois, Policlinique médicale universitaire (Lausanne) , 2011/05. 2 p..
Mise en place percutanée de filtres dans la veine cave inférieure en prévention de l'embolie pulmonaire : recommandations
Mazzolai L., Qanadli S., 2011/04. 7 p..
 
Alexithymia in patients recently diagnosed with cancer
Stiefel F., Krenz S., Forni V., Zdrojewski C., Aymon N., Stagno D., Luthi F., Leyvraz S., Rousselle I., Ludwig G., 2011. p. 616 dans 14th Annual Meeting of the European Association for Consultation Liaison Psychiatry and Psychosomatics (EACLPP), Journal of Psychosomatic Research. Peer-reviewed.
 
Alexithymie et psychopathologie de patients atteints de cancer = Alexithymia and psychopathology of patients with cancer
Forni V., Stiefel F., Krenz S., Gholam Rezaee M., Leyvraz S., Ludwig G., 2011. Psycho-Oncologie, 5 (3) pp. 208-213. Peer-reviewed.
 
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan M.M., Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., Forbes J.F., Smith I., Láng I., Wardley A. et al., 2011. Lancet Oncology, 12 (12) pp. 1101-1108.
 
Breast sarcomas: current and future perspectives.
Voutsadakis I.A., Zaman K., Leyvraz S., 2011. Breast, 20 (3) pp. 199-204.
Diffusion-weighted MRI in metastatic gastrointestinal tumours (GIST): a pilot study on the assessment of treatment response in comparison with 18 F-FDG PET/CT
Koehli M., Dunet V., Montemurro M., Leyvraz S., Meuli R., Prior J., Schmidt S., 2011. dans ECR 2011, European Congress of Radiology.
 
Improvement of therapeutic drug monitoring of imatinib by Bayesian prediction of trough levels. Personalized drug dosage
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. p. 478 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Induction treatment in sarcoma
Matter M., Gay B., Christinat A., Zouhair A., Leyvraz S., 2011. pp. 267-302 dans Aigner K.R., Stephens F.O. (eds.) Induction chemotherapy : integrated treatment programs for locally advanced cancers chap. 21, Springer.
 
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Regan M.M., Price K.N., Giobbie-Hurder A., Thürlimann B., Gelber R.D., International Breast Cancer Study Group, BIG 1-98 Collaborative Group, 2011. Breast Cancer Research, 13 (3) p. 209.
 
Lymphodepletion by short-term chemotherapy does not alter the highly stable and persistent EBV specific CD8 T cell repertoire
Iancu E.M., Laurent J., Wieckowski S., Gupta B., Leyvraz S., Meylan P., Romero P., Michelin O., Speiser D., Rufer N., 2011. pp. 101-102 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
 
Mélanome: une nouvette ère thérapeutique [Melanoma: a new therapeutic era].
Berthod G., Homicsko K., Bouchaab H., Matter M., Cerottini J.P., Guggisberg D., Speiser D., Leyvraz S., Michielin O., 2011. Revue Médicale Suisse, 7 (296) pp. 1126-1130.
 
Personalized drug dosage: Monitoring of imatinib concentration with a Bayesian interpretation tool
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. dans Nano-Tera Annual Plenary Meeting.
 
Psychodynamic psychotherapy in newly diagnosed cancer patients: a randomized controlled trial
Krenz S., Zdrojewski C., Aymon N., Stagno D., Luthi F., Fucina N., Leyvraz S., Rousselle I., Stiefel F., Ludwig G., 2011. p. 602 dans 14th Annual Meeting of the European Association for Consultation Liaison Psychiatry and Psychosomatics (EACLPP), Journal of Psychosomatic Research. Peer-reviewed.
Adhésion thérapeutique en oncologie : persistance, qualité d'exécution et satisfaction des patients sous traitement oral et MEMS®
Jeanneret L., Schneider M.P., Domingues S., Guignard Hefti E., Lange A.C., Vrijens B., Bauer J., Leyvraz S., Bugnon O., Luthi F., 2010. dans 78e Assemblée Annuelle de la SSMI 2010 Société Suisse de Médecine Interne.
 
An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A., 2010. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 878 (32) pp. 3402-3414.
 
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Hogendoorn P.C., ESMO/EUROBONET Working Group, Athanasou N., Athanasou N., Bielack S., De Alava E., Dei Tos A.P., Ferrari S., Gelderblom H., Grimer R. et al., 2010. Annals of Oncology, 21 Suppl 5 (Suppl. 5) pp. v204-v213.
 
Diffusion-weighted MRI in metastatic gastrointestinal tumors (GIST): A pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT
Koehli M., Dunet V., Montemurro M., Leyvraz S., Meuli R., Prior J.O., Schmidt S., 2010. p. 12 dans Swiss Radiological Congress 2010, Schweizerische Gesellschaft für Radiologie, Schweizerische Gesellschaft für Nuklearmedizin, Schweizerische Vereinigung der Fachleute für medizinisch technische Radiologie, Swiss Medical Forum = Forum Médical Suisse.
Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia.
Lüthi F., Pless M., Leyvraz S., Biedermann B., Müller E., Hermann R., Monnerat C., 2010. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 18 (12) pp. 1515-1520.
 
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali P.G., Blay J.Y., ESMO/CONTICANET/EUROBONET Consensus Panel of Experts, 2010. Annals of Oncology, 21 Suppl 5 pp. v98-102.
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Widmer N., Decosterd L.A., Csajka C., Montemurro M., Haouala A., Leyvraz S., Buclin T., 2010. British Journal of Cancer, 102 (7) pp. 1198-1199. Peer-reviewed.
 
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Laurent J., Speiser D.E., Appay V., Touvrey C., Vicari M., Papaioannou A., Canellini G., Rimoldi D., Rufer N., Romero P. et al., 2010. Journal of Immunotherapy, 33 (7) pp. 723-734.
 
IRM de diffusion et GIST métastatique : évaluation de la réponse thérapeutique comparée à la 18-FDG-TEP-TDM
Koehli M., Dunet V., Montemurro M., Leyvraz S., Meuli R., Prior J.O., Schmidt S., 2010. p. 1324 dans JFR 2010, 58e Journées Françaises de Radiologie, Journal de Radiologie. Peer-reviewed.
 
Oncologie médicale: la renaissance revisitée... [Medical oncology: the Renaissance revisited...]
Aapro M.S., Leyvraz S., Sappino A.P., 2010. Revue Médicale Suisse, 6 (250) p. 1043.
Oral cancer treatments and compliance : MEMS® assessment for capecitabine, letrozole and exemestane
Achtari Jeanneret L., Luthi F., Guignard Hefti E., Schneider M.P., Lange A.C., Pachinger C., Montemurro M., Bauer J., Naoux R., Bugnon O. et al., 2010. dans Berlin 2009 Congress, European Society for Medical Oncology (ESMO).
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
 
Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali P.G., Blay J.Y., ESMO/CONTICANET/EUROBONET Consensus Panel of experts, 2010. Annals of Oncology, 21 Suppl 5 (Suppl. 5) pp. v198-v203.
 
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
Moreau P., Hulin C., Marit G., Caillot D., Facon T., Lenain P., Berthou C., Pégourié B., Stoppa A.M., Casassus P. et al., 2010. Leukemia, 24 (6) pp. 1233-1235.
Survey of Biobanks at a Swiss University Hospital
Currat-Zweifel C., Leyvraz S., Simeon-Dubach D., Horisberger J.D., Stamenkovic I., 2010. dans ISBER 2010 Annual Meeting and Exhibits, Diversity in Biobanking: Embracing Differences, Harnessing Commonalities.
 
Traitements antiangiogéniques des cancers métastatiques du côlon et du rectum, du sein et du poumon: bénéfices et risques [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]
Wagner A.D., Zaman K., Peters S., Montemurro M., Leyvraz S., 2010. Revue Médicale Suisse, 6 (250) pp. 1070-1073. Peer-reviewed.
Current standards and progress in understanding and treatment of GIST.
Dirnhofer S., Leyvraz S., 2009/02/21. Swiss medical weekly, 139 (7-8) pp. 90-102. Peer-reviewed.
 
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
Le Cesne A., Van Glabbeke M., Verweij J., Casali P.G., Findlay M., Reichardt P., Issels R., Judson I., Schoffski P., Leyvraz S. et al., 2009. Journal of Clinical Oncology, 27 (24) pp. 3969-3974.
 
Badminton, rectal cancer and 25 kg weight gain during chemotherapy.
Riklin Christian, Guntern Daniel, Leyvraz Serge, Montemurro Michael, 2009. Acta Oncologica, 48 (8) pp. 1208-1210.
 
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
Rabaglio M., Sun Z., Price K.N., Castiglione-Gertsch M., Hawle H., Thürlimann B., Mouridsen H., Campone M., Forbes J.F., Paridaens R.J. et al., 2009. Annals of Oncology, 20 (9) pp. 1489-1498.
 
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Giobbie-Hurder A., Price K.N., Gelber R.D., International Breast Cancer Study Group, BIG 1-98 Collaborative Group, 2009. Clinical Trials, 6 (3) pp. 272-287.
 
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior J.O., Montemurro M., Orcurto M.V., Michielin O., Luthi F., Benhattar J., Guillou L., Elsig V., Stupp R., Delaloye A.B. et al., 2009. Journal of Clinical Oncology, 27 (3) pp. 439-445. Peer-reviewed.
 
Epithelioid soft tissue tumors.
Dei Tos A.P., Wagner A.J., Modena P., Comandone A., Leyvraz S., 2009. Seminars in Oncology, 36 (4) pp. 347-357. Peer-reviewed.
 
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Pagani O., Gelber S., Simoncini E., Castiglione-Gertsch M., Price K.N., Gelber R.D., Holmberg S.B., Crivellari D., Collins J., Lindtner J. et al., 2009. Breast Cancer Research and Treatment, 116 (3) pp. 491-500.
 
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
Thürlimann B., Price K.N., Gelber R.D., Holmberg S.B., Crivellari D., Colleoni M., Collins J., Forbes J.F., Castiglione-Gertsch M., Coates A.S. et al., 2009. Breast Cancer Research and Treatment, 113 (1) pp. 137-144.
 
La surveillance active dans la prise en charge du cancer de la prostate précoce. [Active surveillance for early-stage prostate cancer]
Jichlinski P., Berthold D. R., Zouhair A., Griesser A. C., Meuwly J. Y., Prior J. O., Lhermitte B., Doerfler A., Treuthardt C., Praz V. et al., 2009. Revue médicale suisse, 5 (228) pp. 2442-4, 2446-7.
 
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group, Mouridsen H., Mouridsen H., Giobbie-Hurder A., Goldhirsch A., Thürlimann B., Paridaens R., Smith I., Mauriac L., Forbes J. et al., 2009. New England Journal of Medicine, 361 (8) pp. 766-776. Peer-reviewed.
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.
Italiano A., Penel N., Robin Y.M., Bui B., Le Cesne A., Piperno-Neumann S., Tubiana-Hulin M., Bompas E., Chevreau C., Isambert N. et al., 2009. Annals of Oncology, 20 (3) pp. 425-430. Peer-reviewed.
 
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Montemurro M., Schöffski P., Reichardt P., Gelderblom H., Schütte J., Hartmann J.T., von Moos R., Seddon B., Joensuu H., Wendtner C.M. et al., 2009. European Journal of Cancer, 45 (13) pp. 2293-2297.
 
Response evaluation in third- and fourth-line treatment of GIST: the role of PET
Montemurro M., Prior J., Leyvraz S., 2009. p. 398 dans 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, EJC Supplements. Peer-reviewed.
Role of trabectedin in the treatment of soft tissue sarcoma.
Christinat A., Leyvraz S., 2009. Oncotargets and Therapy, 2 (9) pp. 105-113. Peer-reviewed.
 
Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST : a retrospective analysis : 10564
Reichardt P., Montemurro M., Gelderblom H., Blay J., Rutkowski P., Bui B., Hartmann J.T., Pink D., Leyvraz S., Schütte J., 2009. pp. 15S dans 2009 ASCO Annual Meeting, Journal of Clinical Oncology. Peer-reviewed.
 
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
Colleoni M., Sun Z., Martinelli G., Basser R.L., Coates A.S., Gelber R.D., Green M.D., Peccatori F., Cinieri S., Aebi S. et al., 2009. Annals of Oncology, 20 (8) pp. 1344-1351.
 
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., Decosterd L.A., 2009. Journal of Chromatography. B, 877 (22) pp. 1982-1996. Peer-reviewed.
 
Validating the HUCH working formulation for stage IV uveal melanoma : a European ophthalmic oncology group (OOG) study.
Kujala E., Eskelin S., Piperno-Neumann S., Desjardins L., Schmittel A., Bechrakis N., Midena E., Grange J.D., Ract-Madoux G., Marshall E. et al., 2008/10. dans Perspectives in Melanoma XII, Fall meeting of the EORTC Melanoma Group.
 
Traitements systémiques du cancer colorectal métastatique [Systemic treatment of metastatic colorectal cancer]
Montemurro M., Achtari L., Röth A., Halkic N., Luthi F., Ozsahin M., Denys A., Bauer J., Demartines N., Leyvraz S., 2008/05/21. Revue medicale suisse, 4 (158) pp. 1254-1257. Peer-reviewed.
 
L'oncogériatrie: incontournable partenaire dans l'enseignement postgradué [Oncogeriatrics: essential partner in postgraduate education]
Aapro M.S., Leyvraz S., Sappino A.-P., 2008/05. Revue Médicale Suisse, 4 (158) pp. 1243-1244. Peer-reviewed.
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S., Pampallona S., Martinelli G., Ploner F., Perey L., Aversa S., Peters S., Brunsvig P., Montes A., Lange A. et al., 2008/04. Journal of the National Cancer Institute, 100 (8) pp. 533-541. Peer-reviewed.
 
Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Voelter V., Schalenbourg A., Pampallona S., Peters S., Halkic N., Denys A., Goitein G., Zografos L., Leyvraz S., 2008. Melanoma Research, 18 (3) pp. 220-224. Peer-reviewed.
Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.
Voelter V., Rufer N., Reynard S., Greub G., Brookes R., Guillaume P., Grosjean F., Fagerberg T., Michielin O., Rowland-Jones S. et al., 2008. International Immunology, 20 (8) pp. 1087-1096. Peer-reviewed.
 
Diagnosis and Treatment of GIST = Gastrointestinal Stromal Tumors
Montemurro M., Dirnhofer St., Borner M., Burkhard R., Demartines N., Furrer M., Guillou L., Kettelhack Ch., Knüsli C., Langer I. et al., 2008. Swiss Medical Forum = Forum Médical Suisse, 8 (30-31) pp. 544-549.
 
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.
Gruber G., Cole B.F., Castiglione-Gertsch M., Holmberg S.B., Lindtner J., Golouh R., Collins J., Crivellari D., Thürlimann B., Simoncini E. et al., 2008. Annals of Oncology, 19 (8) pp. 1393-1401.
 
Gastrointestinale Stromatumore
Montemurro M., Schmid A., Dirnhofer S., Metzger U., Röth A., von Moos R., Langer I., Leyvraz S., 2008. Aktuell Onkologie 2 pp. 10-15.
 
Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.
Voelter V., Diserens A.C., Moulin A., Nagel G., Yan P., Migliavacca E., Rimoldi D., Hamou M.F., Kaina B., Leyvraz S. et al., 2008. International Journal of Cancer, 123 (5) pp. 1215-1218. Peer-reviewed.
 
Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients
Cherix S., Speiser M., Matter M., Raffoul W., Liénard D., Theumann N., Mouhsine E., Mirimanoff R.O., Leyvraz S., Lejeune F.J. et al., 2008. Jounal of Surgical Oncology, 98 (3) pp. 148-155. Peer-reviewed.
 
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.
Moreau P., Garban F., Attal M., Michallet M., Marit G., Hulin C., Benboubker L., Doyen C., Mohty M., Yakoub-Agha I. et al., 2008. Blood, 112 (9) pp. 3914-3915. Peer-reviewed.
 
Mature T-cell lymphoma patients show high relapse rates after high dose therapy followed by autologous transplantation.
Nickelsen M., Canals C., Schmitz N., Leyvraz S., Finke J., Koza V., Relander T., Holowiecki J., Linkesch W., Losonczy H. et al., 2008. dans 34th Annual Meeting of the European Group for Blood and Marrow Transplantation EBMT.
Meaning in life assessed with the "Schedule for Meaning in Life Evaluation" (SMiLE): a comparison between a cancer patient and student sample.
Stiefel F., Krenz S., Zdrojewski C., Stagno D., Fernandez M., Bauer J., Fucina N., Lüthi F., Leyvraz S., Borasio G.D. et al., 2008. Supportive Care in Cancer, 16 (10) pp. 1151-1155. Peer-reviewed.
 
Nilotinib compassionate use in advanced GIST : a retrospective analysis
Montemurro M., Schöffski P., Pink D., Gelderblom H., Joensuu H., Schütte J., von Moos R., Wendtner C.M., Seddon B., Leyvraz S., 2008. pp. viii268 dans 33rd ESMO Congress, Annals of oncology. Peer-reviewed.
 
Nilotinib in advanced GIST : a retrospective analysis of nilotinib in compassionate use
Montemurro M., Schöffski P., Reichardt P., Gelderblom H., Joensuu H., Schütte J., Wendtner C.M., Hartmann J.T., Elsig V., Leyvraz S., 2008. p. 10523 dans 30th Annual meeting of the ASCO, Journal of Clinical Oncology. Peer-reviewed.
 
Nouveautés dans l'immunothérapie du cancer [New developments in cancer immunotherapy]
Michielin O., Rufer N., Romero P., Laurent J., Cerottini J.P., Gugisberg D., Leyvraz S., Speiser D., 2008. Revue Médicale Suisse, 4 (158) pp. 1248-1251.
 
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
Ravaioli A., Monti F., Regan M.M., Maffini F., Mastropasqua M.G., Spataro V., Castiglione-Gertsch M., Panzini I., Gianni L., Goldhirsch A. et al., 2008. Annals of Oncology, 19 (4) pp. 660-668.
 
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M, 2008. Lung Cancer, 64 (1) pp. 60-65. Peer-reviewed.
 
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Viale G., Giobbie-Hurder A., Regan M.M., Coates A.S., Mastropasqua M.G., Dell'Orto P., Maiorano E., MacGrogan G., Braye S.G., Ohlschlegel C. et al., 2008. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 26 (34) pp. 5569-5575.
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Widmer N., Decosterd L. A., Leyvraz S., Duchosal M. A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2008. British Journal of Cancer, 98 (10) pp. 1633-1640. Peer-reviewed.
Response: Re: 'A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small-Cell Lung Cancer: A Randomized Trial'
Pampallona S., Leyvraz S., 2008. JNCI Journal of the National Cancer Institute, 101 (1) pp. 67-68.
 
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Casali P.G., Jost L., Sleijfer S., Verweij J., Blay J.Y., ESMO Guidelines Working Group, 2008. Annals of Oncology, 19 Suppl 2 (Suppl. 2) pp. ii89-ii93.
 
Tyrosinkinase - Inhibition (Editorial)
Michael M., Leyvraz S., 2008. Aktuell Onkologie 2 pp. 3-4.
 
Cancers de l'adulte jeune [Overview on cancer in young adults]
Nay C., Luthi F., Ketterer N., Bauer J., Leyvraz S., 2007. Revue médicale suisse, 3 (112) pp. 1305-6, 1308-10.
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widmer N., Leyvraz S., Duchosal M.A., Rosselet A., Csajka C., Henry H., Debiec-Rychter M., Eap C.B., Biollaz J., Buclin T. et al., 2007. p. 481 dans 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V., Voelter V., Rufer N., Reynard S., Jandus C., Gasparini D., Lienard D., Speiser D.E., Schneider P., Cerottini J.C. et al., 2007. Journal of Immunotherapy, 30 (2) pp. 240-250. Peer-reviewed.
 
Depression among cancer patients: a randomised controlled trial comparing standard care with short psychodynamic psychotherapy
Stagno Danièle, Stiefel Friedrich, Irenz S. L., Zdrojewski C., Lüthi F., Leyvraz Serge, 2007. p. 108 dans , Psychotherapie, Psychosomatik, medizinische Psychologie. Peer-reviewed.
 
Development of a method investigating meaning in life in cancer patients
Krenz Sonia, Stagno Danièle, Zdrojewski C., Lüthi F., Leyvraz Serge, Stiefel Friedrich, 2007. pp. 91-92 dans , Psychotherapie, Psychosomatik, medizinische Psychologie. Peer-reviewed.
 
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
International Breast Cancer Study Group, Colleoni M., Colleoni M., Gelber S., Simoncini E., Pagani O., Gelber R.D., Price K.N., Castiglione-Gertsch M., Coates A.S. et al., 2007. Annals of Oncology, 18 (7) pp. 1177-1184.
 
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., Leyvraz S., Michallet M., Yakoub-Agha I., Garderet L. et al., 2007. Blood, 109 (8) pp. 3489-95. Peer-reviewed.
 
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
Moreau P., Attal M., Garban F., Hulin C., Facon T., Marit G., Michallet M., Doyen C., Leyvraz S., Mohty M. et al., 2007. Leukemia, 21 (9) pp. 2020-2024. Peer-reviewed.
Impact of family structure on long-term survivors of osteosarcoma.
Bressoud A., Real del Sarte O., Stiefel S., Mordasini P., Perey L., Bauer J., Leyvraz P.F., Leyvraz S., 2007. Supportive Care in Cancer, 15 (5) pp. 525-531. Peer-reviewed.
 
Phenotypic and functional analysis of human fetal liver hematopoietic stem cells in culture.
Rollini P., Faes-Van't Hull E., Kaiser S., Kapp U., Leyvraz S., 2007. Stem cells and development, 16 (2) pp. 281-96. Peer-reviewed.
 
Plaidoyer pour une oncologie régionale concertée: l'exemple lémanique [Regional hospital, clinic, and physician collaboration in oncology care]
Sappino A.P., Leyvraz S., 2007. Revue médicale suisse, 3 (112) pp. 1283-4.
 
Relations entre les taux plasmatiques d'imatinib et ses effets cliniques
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. dans 14es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationships between imatinib plasma levels and efficacy
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. pp. 80S dans 75. Jahresversammlung der Schweizerisches Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages.
Appay V., Bosio A., Lokan S., Wiencek Y., Biervert C., Küsters D., Devevre E., Speiser D., Romero P., Rufer N. et al., 2007. Journal of Immunology, 179 (11) pp. 7406-7414. Peer-reviewed.
 
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Leyvraz S., Herrmann R., Guillou L., Honegger H.P., Christinat A., Fey M.F., Sessa C., Wernli M., Cerny T., Dietrich D. et al., 2006/11/20. British journal of cancer, 95 (10) pp. 1342-1347. Peer-reviewed.
 
CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.
Voelter V., Zouhair A., Vuilleumier H., Matter M., Bouzourene H., Leyvraz S., Bauer J., Coucke P., Stupp R., 2006. British journal of cancer, 95 (6) pp. 710-6. Peer-reviewed.
 
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V., Speiser D.E., Rufer N., Reynard S., Barbey C., Cerottini J.C., Leyvraz S., Pinilla C., Romero P., 2006. European journal of immunology, 36 (7) pp. 1805-14. Peer-reviewed.
 
Depression among cancer patients: a randomised controlled trial comparing standard care with a short psychodynamic psychotherapy
Stiefel Friedrich, Krenz Sonia, Zdrojewski C., Lüthi F., Leyvraz Serge, Stagno Danièle, 2006. pp. 16-17 dans , Psycho-Oncology. Peer-reviewed.
 
Development of a method investigating meaning in life in cancer patients
Stagno Danièle, Krenz Sonia, Zdrojewski C., Lüthi F., Leyvraz Serge, Stiefel Friedrich, 2006. p. 16 dans , Psycho-Oncology. Peer-reviewed.
 
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Bay J.O., Ray-Coquard I., Fayette J., Leyvraz S., Cherix S., Piperno-Neumann S., Chevreau C., Isambert N., Brain E., Emile G. et al., 2006. International journal of cancer. Journal international du cancer, 119 (3) pp. 706-11. Peer-reviewed.
 
Effect of computerisation on the quality and safety of chemotherapy prescription.
Voeffray M., Pannatier A., Stupp R., Fucina N., Leyvraz S., Wasserfallen J.B., 2006. Quality & safety in health care, 15 (6) pp. 418-21.
 
Expression of Chemokine Receptors in Uveal Melanoma
Moulin A.P., Yan P., Rimoldi D., Leyvraz S., Schalenbourg A., Zografos L., Bosman F.T., 2006., Association for Research in Vision and Ophthalmology dans ARVO E-Abstract 2215-B958. Peer-reviewed.
 
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults.
Pedrazzoli P., Ledermann J.A., Lotz J.P., Leyvraz S., Aglietta M., Rosti G., Champion K.M., Secondino S., Selle F., Ketterer N. et al., 2006. Annals of Oncology, 17 (10) pp. 1479-1488. Peer-reviewed.
 
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.
Appay V., Reynard S., Voelter V., Romero P., Speiser D.E., Leyvraz S., 2006. Journal of immunological methods, 309 (1-2) pp. 192-9. Peer-reviewed.
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
Peters S., Voelter V., Zografos L., Pampallona S., Popescu R., Gillet M., Bosshard W., Fiorentini G., Lotem M., Weitzen R. et al., 2006. Annals of Oncology, 17 (4) pp. 578-583. Peer-reviewed.
 
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Debiec-Rychter M., Sciot R., Le Cesne A., Schlemmer M., Hohenberger P., van Oosterom A.T., Blay J.Y., Leyvraz S., Stul M., Casali P.G. et al., 2006. European Journal of Cancer, 42 (8) pp. 1093-1103. Peer-reviewed.
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
Leyvraz S., Zweifel M., Jundt G., Lissoni A., Cerny T., Sessa C., Fey M., Dietrich D., Honegger H.P. and , 2006. Annals of Oncology, 17 (4) pp. 646-651. Peer-reviewed.
 
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Attal M., Harousseau J.L., Leyvraz S., Doyen C., Hulin C., Benboubker L., Yakoub Agha I., Bourhis J.H., Garderet L., Pegourie B. et al., 2006. Blood, 108 (10) pp. 3289-94. Peer-reviewed.
 
Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
Zaman K., Driscoll R., Hahn D., Werffeli P., Goodman S.L., Bauer J., Leyvraz S., Lejeune F., Stupp R., Rüegg C., 2006. International journal of cancer. Journal international du cancer, 118 (3) pp. 755-64. Peer-reviewed.
 
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
Appay V., Jandus C., Voelter V., Reynard S., Coupland S.E., Rimoldi D., Lienard D., Guillaume P., Krieg A.M., Cerottini J.C. et al., 2006. Journal of Immunology, 177 (3) pp. 1670-1678. Peer-reviewed.
 
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. British journal of clinical pharmacology, 62 (1) pp. 97-112. Peer-reviewed.
 
Relations entre la pharmacocinétique de population de l'imatinib et l'alpha-1-glycoproteine acide chez des patients hémato-oncologiques
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. dans 13es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationship between imatinib population pharmacokinetics and alpha-1-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. pp. 71S dans 74e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Urgences oncologiques : chapitres choisis
Peters S, Luthi F, Leyvraz S., 2006. Forum Médical Suisse 33 pp. 718-725.
 
L'indépendance de la recherche clinique survivra-t-elle [Can independent clinical research survive?].
Aapro M.S., Leyvraz S., 2005/05. Revue Médicale Suisse, 1 (20) pp. 1323-1324.
 
Le depistage du cancer. [Cancer screening: when and how?]
Leupin N., Bauer J., Luthi F., Lienard D., Vulliemoz D., Leyvraz S., 2005/05. Revue Médicale Suisse, 1 (20) pp. 1328-30, 1333-4.
 
Les liaisons dangereuses: interactions entre medecins de premier recours et oncologues medicaux. [Dangerous liaisons: relation between oncologist and general practitioner]
Bauer J., Leyvraz S., 2005/05. Revue Médicale Suisse, 1 (20) pp. 1356-8.
 
Les nouvelles thérapies systémiques en oncologie [New systemic therapies in oncology].
Zaman K., Ketterer N., Vulliémoz D., Stupp R., Leyvraz S., 2005/05. Revue Médicale Suisse, 1 (20) pp. 1361-2, 1364-5.
 
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Wasserfallen J.B., Ostermann S., Leyvraz S., Stupp R., 2005/04. Neuro-Oncology, 7 (2) pp. 189-195. Peer-reviewed.
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
Goerres G.W., Stupp R., Barghouth G., Hany T.F., Pestalozzi B., Dizendorf E., Schnyder P., Luthi F., von Schulthess G.K., Leyvraz S., 2005/02. European Journal of Nuclear Medicine and Molecular Imaging, 32 (2) pp. 153-162. Peer-reviewed.
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of soft tissue sarcomas.
Leyvraz S., Jelic S., ESMO Guidelines Task Force, 2005. Annals of Oncology, 16 Suppl 1 (Suppl. 1) pp. 69-70. Peer-reviewed.
 
L'annonce d'une mauvaise nouvelle en oncologie [Breaking bad news]
Voelter V., Mirimanoff R.O., Stiefel F., Rousselle I., Leyvraz S., 2005. Revue médicale suisse, 1 (20) pp. 1350, 1352-3.
 
Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.
Montes M., Rufer N., Appay V., Reynard S., Pittet M.J., Speiser D.E., Guillaume P., Cerottini J.C., Romero P., Leyvraz S., 2005. Clinical and experimental immunology, 142 (2) pp. 292-302. Peer-reviewed.
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 116-117 dans 7th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 63S dans 73e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party
Rosti G., De Giorgi U., Wandt H., Lioure B., Leyvraz S., Kolbe K., Papiani G., Ballardini M., Kulekci A., Demirer T., 2004/12. Bone Marrow Transplantation, 34 (12) pp. 1033-7.
 
Small cell lung cancer: state of the art and future perspectives
Stupp R., Monnerat C., Turrisi, A. T., 3rd , Perry M. C., Leyvraz S., 2004/07. Lung Cancer, 45 (1) pp. 105-17.
 
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L. A., Stupp R., 2004/06. Clinical Cancer Research, 10 (11) pp. 3728-36.
 
Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
Widmer N., Beguin A., Rochat B., Buclin T., Kovacsovics T., Duchosal M. A., Leyvraz S., Rosselet A., Biollaz J., Decosterd L. A., 2004/04. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 803 (2) pp. 285-292. Peer-reviewed.
 
Long-term expansion of transplantable human fetal liver hematopoietic stem cells
Rollini P., Kaiser S., Faes-van't Hull E., Kapp U., Leyvraz S., 2004/02. Blood, 103 (3) pp. 1166-70.
 
The origin of brain metastases in patients with an undiagnosed primary tumour
Agazzi S., Pampallona S., Pica A., Vernet O., Regli L., Porchet F., Villemure J. G., Leyvraz S., 2004/02. Acta Neurochirurgica, 146 (2) pp. 153-7.
 
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Wasserfallen J.B., Ostermann S., Pica A., Mirimanoff R.O., Leyvraz S., Villemure J.G., Stupp R., 2004. Cancer, 101 (9) pp. 2098-2105. Peer-reviewed.
 
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
International Breast Cancer Study Group, Pagani O., Pagani O., Gelber S., Price K., Zahrieh D., Gelber R., Simoncini E., Castiglione-Gertsch M., Coates A.S. et al., 2004. Annals of Oncology, 15 (12) pp. 1749-1759.
 
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days
Vouillamoz-Lorenz S., Buclin T., Lejeune F., Bauer J., Leyvraz S., Decosterd L. A., 2003/06. Anticancer Research, 23 (3C) pp. 2757-65.
 
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions.
Rufer N., Zippelius A., Batard P., Pittet M.J., Kurth I., Corthesy P., Cerottini J.C., Leyvraz S., Roosnek E., Nabholz M. et al., 2003. Blood, 102 (5) pp. 1779-87. Peer-reviewed.
 
Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study.
Voelter V., Stupp R., Matter M., Gillet M., Bouzourene H., Leyvraz S., Coucke P., 2003. International journal of radiation oncology, biology, physics, 56 (5) pp. 1288-94. Peer-reviewed.
 
The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer
Prior J. O., Barghouth G., Delaloye J. F., Leyvraz S., Bischof Delaloye A., 2003/01. Nuclear Medicine Communications, 24 (1) pp. 29-36.
 
Long-term ex vivo expansion of human fetal liver primitive haematopoietic progenitor cells in stroma-free cultures
Peters R., Leyvraz S., Faes-Van't Hull E., Jaunin P., Gerber S., Rollini P., 2002/12. British Journal of Haematology, 119 (3) pp. 792-802.
 
High-dose chemotherapy for solid tumors: results of the EBMT
Rosti G., Ferrante P., Ledermann J., Leyvraz S., Ladenstein R., Koscileniak E., Crown J., Dazzi C., Cariello A., Marangolo M., 2002/02. Critical Reviews in Oncology/Hematology, 41 (2) pp. 129-40.
 
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG), 2002. Journal of the National Cancer Institute, 94 (14) pp. 1054-1065.
 
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R., Dietrich P.Y., Ostermann Kraljevic S., Pica A., Maillard I., Maeder P., Meuli R., Janzer R., Pizzolato G., Miralbell R. et al., 2002. Journal of Clinical Oncology, 20 (5) pp. 1375-1382. Peer-reviewed.
High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR
Perey L., Benhattar J., Peters R., Jaunin P., Leyvraz S., 2001/11. British Journal of Cancer, 85 (11) pp. 1713-21.
 
Current and future developments in the use of temozolomide for the treatment of brain tumours
Stupp R., Gander M., Leyvraz S., Newlands E., 2001/09. Lancet Oncology, 2 (9) pp. 552-60.
 
Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.
Stupp R., Bodmer A., Duvoisin B., Bauer J., Perey L., Bakr M., Ketterer N., Leyvraz S., 2001. Oncology, 61 Suppl 1 pp. 35-41. Peer-reviewed.
 
Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Lejeune F.J., Pujol N., Liénard D., Mosimann F., Raffoul W., Genton A., Guillou L., Landry M., Chassot P.G., Chiolero R. et al., 2000/11. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 26 (7) pp. 669-678. Peer-reviewed.
 
Haematopoietic stem cell transplant activity in Switzerland 1997/1998: a report by the STABMT. Swisstransplant Working Group Blood and Marrow Transplantation.
Passweg J, Baldomero H, Gmür J, Bargetzi M, Cavalli F, Ghielmini M, Helg C, Hess U, Herrmann R, Jost L et al., 2000. Schweizerische Medizinische Wochenschrift, 130 (27-28) pp. 1027-1033.
 
Thalidomide in patients with advanced multiple myeloma
Yakoub-Agha I., Moreau P., Leyvraz S., Berthou C., Payen C., Dumontet C., Grosbois B., Beris P., Duguet C., Attal M. et al., 2000. Hematology Journal, 1 (3) pp. 186-9.
Little to learn from phase II trials in small-cell lung cancer
Leyvraz S., Stupp R., 1999/09. Annals of Oncology, 10 (9) pp. 1007-9.
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours
Gander M., Leyvraz S., Decosterd L., Bonfanti M., Marzolini C., Shen F., Lienard D., Perey L., Colella G., Biollaz J. et al., 1999/07. Annals of Oncology, 10 (7) pp. 831-8.
 
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
Woll P. J., Judson I., Lee S. M., Rodenhuis S., Nielsen O. S., Buesa J. M., Lorigan P. C., Leyvraz S., Hermans C., van Glabbeke M. et al., 1999/03. European Journal of Cancer, 35 (3) pp. 410-2.
Cost comparison between PAV and ICE treatment with peripheral blood progenitor cells (PBPC) reinfusion in small-cell lung cancer (SCLC)
Wasserfallen J. B., Rollier P., Leyvraz S., Perey L., 1999/02. Annals of Oncology, 10 (2) pp. 243-4.
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
Couteau C., Chouaki N., Leyvraz S., Oulid-Aissa D., Lebecq A., Domenge C., Groult V., Bordessoule S., Janot F., De Forni M. et al., 1999. British Journal of Cancer, 81 (3) pp. 457-462.
 
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Leyvraz S., Perey L., Rosti G., Lange A., Pampallona S., Peters R., Humblet Y., Bosquée L., Pasini F., Marangolo M., 1999. Journal of Clinical Oncology, 17 (11) pp. 3531-3539. Peer-reviewed.
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
Cerny T., Leyvraz S., von Briel T., Küpfer A., Schaad R., Schmitz S.F., Honegger P., Sessa C., Brunner J., Boddy A.V., 1999. Annals of Oncology, 10 (9) pp. 1087-1094.
 
Tumoranämie. Ubersicht über die Rolle des humanen rekombinanten Erythropoetins (r-hu-EPO) bei der Behandlung der Tumoranämie [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C., Leyvraz S., 1999/01. Praxis, 88 (5) pp. 178-188.
 
Extensive phenotypic analysis of CD34 subsets in successive collections of mobilized peripheral blood progenitors
Perey L., Peters R., Pampallona S., Schneider P., Gross N., Leyvraz S., 1998/12. British Journal of Haematology, 103 (3) pp. 618-29.
 
Adenocarcinoma of the small bowel, coeliac disease, and lymphocytic gastritis
Widgren S., Leyvraz S., 1998/11. Journal of Clinical Pathology, 51 (11) pp. 878-9.
 
Apoptotic regulation in primitive hematopoietic precursors
Peters R., Leyvraz S., Perey L., 1998/09. Blood, 92 (6) pp. 2041-52.
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK)
Leyvraz S., Bacchi M., Cerny T., Lissoni A., Sessa C., Bressoud A., Hermann R., 1998/08. Annals of Oncology, 9 (8) pp. 877-84.
 
The Family System Test (FAST). A pilot study in families with a young adult member with cancer
Real del Sartre, Stiefel F., Leyvraz S., Bauer J., Gehring T. M., Guex P., 1998/07. Supportive Care in Cancer, 6 (4) pp. 416-20.
 
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)
Borner M. M., Castiglione M., Bacchi M., Weber W., Herrmann R., Fey M. F., Pagani O., Leyvraz S., Morant R., Pestalozzi B. et al., 1998/05. Annals of Oncology, 9 (5) pp. 535-41.
 
Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy.
Salmon R.J., Levy C., Plancher C., Dorval T., Desjardins L., Leyvraz S., Pouillart P., Schlienger P., Servois V., Asselain B., 1998/04. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 24 (2) pp. 127-130. Peer-reviewed.
 
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C., Decosterd L.A., Shen F., Gander M., Leyvraz S., Bauer J., Buclin T., Biollaz J., Lejeune F., 1998. Cancer Chemotherapy and Pharmacology, 42 (6) pp. 433-440.
 
Reverse transcriptase-polymerase chain reaction and islet cell carcinoma: not antagonist, but complementary tools.
Benhattar J., Perey L., Peters R., Leyvraz S., 1998. Journal of Clinical Oncology, 16 (2) pp. 806-807. Peer-reviewed.
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial.
Stupp R., Bauer J., Pagani O., Gerard B., Cerny T., Sessa C., Bastian G., Sarkany M., Schläpfer J., Giroux B. et al., 1998. Annals of Oncology, 9 (11) pp. 1233-1242. Peer-reviewed.
A rare case of prednimustine-induced myoclonus
Monnerat C., Gander M., Leyvraz S., 1997/01. Journal of the National Cancer Institute, 89 (2) pp. 173-4.
 
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
Sarcoma Meta-analysis Collaboration, 1997. Lancet, 350 (9092) pp. 1647-1654.
 
Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn H.J., Maibach R., Castiglione M., Jungi W.F., Cavalli F., Leyvraz S., Obrecht J.P., Schildknecht O., Siegenthaler P., 1997. Journal of Clinical Oncology, 15 (7) pp. 2502-2509. Peer-reviewed.
 
Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
Castiglione M, Goldhirsch A, Gusterson B, Bettelheim R, Reed R, Gusset H, Geiser K, Hurny C, Bernhard J, Hangartner A et al., 1997. Journal of Clinical Oncology, 15 (4) pp. 1385-1394. Peer-reviewed.
 
Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy.
Leyvraz S., Spataro V., Bauer J., Pampallona S., Salmon R., Dorval T., Meuli R., Gillet M., Lejeune F., Zografos L., 1997. Journal of Clinical Oncology, 15 (7) pp. 2589-2595. Peer-reviewed.
 
Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK)
Bernhard J., Hurny C., Bacchi M., Joss R. A., Cavalli F., Senn H. J., Leyvraz S., Stahel R., Ludwig C., Alberto P., 1996/11. British Journal of Cancer, 74 (10) pp. 1660-7.
 
Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study
Perey L., Rosti G., Lange A., Pampallona S., Bosquee L., Pasini F., Humblet Y., Hamdan O., Cetto G. L., Marangolo M. et al., 1996/09. Bone Marrow Transplantation, 18 Suppl 1 pp. S40-3.
 
Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix.
Delaloye J.F., Leyvraz S., Outcha Adjahoto E., Bauer J., De Grandi P., 1996/04. American Journal of Clinical Oncology, 19 (2) pp. 204-206. Peer-reviewed.
 
Infrequent expression of the MAGE gene family in uveal melanomas.
Mulcahy K.A., Rimoldi D., Brasseur F., Rodgers S., Liénard D., Marchand M., Rennie I.G., Murray A.K., McIntyre C.A., Platts K.E. et al., 1996. International journal of cancer. Journal international du cancer, 66 (6) pp. 738-42. Peer-reviewed.
 
Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation
Buser K., Bacchi M., Goldhirsch A., Greiner R., Diener P., Sessa C., Jungi W. F., Forni M., Leyvraz S., Engeler V., 1996/01. Annals of Oncology, 7 (1) pp. 65-70.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University